-
-
-
-
-
-
-
Disc Medicine (IRON) Misses Q1 EPS by 1c
-
-
-
-
-
-
-
Morgan Stanley says 'buy the dip' in Disc Medicine (IRON)
-
-
-
-
-
-
-
BMO on Disc Medicine (IRON) Post Mgmt Call: 'management indicated that FDA has given no indication that the NDA review process is currently at risk'
-
-
-
-
-
-
-
Disc Medicine submits drug application, receives priority review voucher
-
-
-
-
-
-
-
Disc Medicine receives FDA priority voucher for EPP drug bitopertin
-
-
-
-
-
-
-
Disc Medicine adds Cullinan Therapeutics CEO to board
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Disc Medicine (IRON)
-
458,137 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

